MarketsFN
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
Stocks

Tilray Brands (TLRY) Q1 2027 Financial Results Summary

QuoteReporter

•4 min read
Tilray Brands (TLRY) Q1 2027 Financial Results Summary

Tilray Brands (TLRY) Q1 2027: Record Revenue and Profitability — Cautiously Optimistic

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) reported a record first-quarter net revenue of $257 million, reflecting a $47.6 million or 23% increase year-over-year. This performance underscores the company's robust growth trajectory across its diversified business segments, particularly in international cannabis, beverages, and pharmaceutical distribution.

Key Financial Metrics

  • Net Revenue: $257 million, up $47.6 million or 23% YoY
  • Gross Profit: $77.5 million, an increase of $20 million or 35% YoY
  • Gross Margin: Expanded by approximately 300 basis points to 30%
  • International Revenue Growth: EMEA revenue increased by 71%
  • Beverage Revenue: $101 million, with a gross margin of 41%
  • Adjusted EBITDA Guidance: Reaffirmed at $68 million to $75 million for fiscal 2027

Analyst Opinion

This quarter represents a significant achievement for Tilray, showcasing its ability to drive revenue growth while expanding profitability. The 23% increase in net revenue and the 35% rise in gross profit are particularly noteworthy, indicating effective operational execution and a strong market presence. However, the company reported a net loss of $40.3 million, a stark contrast to the $1.5 million profit from the same quarter last year, which raises concerns about the sustainability of its current growth strategy.

The increase in operational expenses, particularly in general and administrative costs, which rose by 40% to $57.6 million, suggests that while Tilray is investing in growth, it must manage these costs effectively to maintain profitability. The reaffirmation of adjusted EBITDA guidance is a positive sign, but investors should remain cautious given the significant net loss.

Shareholder Returns and Financial Health

Tilray has demonstrated a commitment to strengthening its balance sheet, having reduced outstanding debt by $42 million year-to-date. The company ended the quarter with cash, restricted cash, and marketable securities totaling $221.4 million, providing it with financial flexibility to pursue strategic growth opportunities.

Forward-Looking Catalysts

Investors should closely monitor Tilray's performance in the upcoming quarters, particularly as the company anticipates stronger results in the second half of the fiscal year due to seasonality. The partnership with Carlsberg to produce and sell iconic brands in the U.S. market starting January 1, 2027, could serve as a significant growth driver. Additionally, the ongoing expansion of its international cannabis and beverage segments will be critical to sustaining momentum.

In conclusion, while Tilray's record revenue and gross profit are commendable, the substantial net loss and rising operational costs warrant a cautious approach from shareholders. The company's ability to navigate these challenges while capitalizing on growth opportunities will be pivotal in determining its future performance.

Consolidated Statements of Income (in thousands of US dollars)

Note: The amounts in the following table are in thousands.

August 31, 2026 August 31, 2025 Change %
Net revenue $ 257,107 $ 209,461 $ 47,646 23
Cost of goods sold 179,598 152,028 27,570 18
Gross profit 77,509 57,469 20,040 35
Operating expenses
General and administrative 57,608 41,053 16,555 40
Selling 13,593 12,923 670 5
Amortization 6,500 3,929 2,571 65
Marketing and promotion 15,736 10,155 5,581 55
Research and development 89 41 48 117
Change in fair value of
contingent consideration — (15,000) 15,000 (100)
Litigation costs, net 787 1,007 (220) (22)
Total operating expenses 101,516 55,377 46,185 83
Operating income (loss) (24,007) 2,092 (26,099) (1250)
Interest expense, net (6,480) (6,696) 216 (3)
Non-operating income (loss) (7,773) 3,832 (11,605) (303)
Income (loss) before income tax (38,260) (772) (37,488) 4862
Income tax expense (recovery) 1,725 (2,285) 4,010 (175)
Net income (loss) $ (40,017) $ 1,513 $ (41,530) (2746)
Total net income (loss) attributable to
stockholders of Tilray Brands (43,136) (322) (42,814) 13298
Non-controlling interests 3,110 1,835 1,275 69
Comprehensive loss $ (35,612) $ 1,325 $ (36,937) (2788)
Total comprehensive income (loss) (38,423) (489) (37,934) 7753
Weighted-average shares used 133,358,356 106,008,213 27,350,143 26
to compute net income per share, basic
Weighted-average shares used 133,358,356 106,008,213 27,350,143 26
to compute net income per share, diluted
Net loss per share - basic $ (0.32) $ (0.00) $ (0.32) 10553
Net loss per share - diluted $ (0.32) $ (0.00) $ (0.32) 10553

Condensed Consolidated Balance Sheets (in thousands of US dollars)

Note: The amounts in the following table are in thousands.

Assets August 31, 2026 May 31, 2026
Current assets
Cash and cash equivalents $ 214,960 $ 225,977
Restricted cash 3,383 3,365
Marketable securities 3,047 5,289
Accounts receivable, net 190,617 189,170
Inventory 328,973 301,192
Prepaids and other current assets 64,160 64,692
Assets held for sale 2,449 2,449
Total current assets 807,589 792,134
Capital assets 665,923 680,225
Operating lease, right-of-use assets 42,030 42,318
Digital assets 720 674
Intangible assets 42,468 42,779
Goodwill 752,350 752,350
Long-term investments 6,365 6,551
Other assets 10,509 10,981
Total assets $ 2,327,954 $ 2,328,012
Liabilities
Current liabilities
Bank indebtedness $ 8,688 $ 8,775
Accounts payable and accrued liabilities 335,415 318,088
Current portion of lease liabilities 11,902 13,357
Current portion of long-term debt 15,457 18,160
Current portion of convertible debentures payable 59,224 —
Total current liabilities 430,686 358,380
Long-term liabilities
Lease liabilities 158,610 158,155
Long-term debt 118,046 120,425
Convertible debentures payable — 79,529
Deferred tax liabilities, net 9,746 12,256
Other liabilities 4,192 4,400
Total liabilities 721,280 733,145
Stockholders' equity
Common stock ($0.0001 par value;
1,416,000,000 common shares authorized;
144,936,074 and 131,683,075 common shares issued and outstanding 145 132
Treasury Stock — —
Preferred shares ($0.0001 par value;
10,000,000 preferred shares authorized;
nil and nil preferred shares issued and outstanding — —
Additional paid-in capital 6,674,469 6,627,056
Accumulated other comprehensive loss (39,492) (44,233)
Accumulated deficit (5,011,764) (4,968,623)
Total Tilray Brands, Inc. stockholders' equity 1,623,358 1,614,332
Non-controlling interests (16,684) (19,465)
Total stockholders' equity 1,606,674 1,594,867
Total liabilities and stockholders' equity $ 2,327,954 $ 2,328,012

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.

Related Articles

Byrna Technologies (BYRN) Q3 2026 Financial Results Summary
Trending
Stocks

Byrna Technologies (BYRN) Q3 2026 Financial Results Summary

QuoteReporter
4 minOct 8, 2026
Tilray Brands (TLRY) Q1 2027: Record Revenue and Profitability — Cautiously Optimistic
Trending
Stocks

Tilray Brands (TLRY) Q1 2027: Record Revenue and Profitability — Cautiously Optimistic

QuoteReporter
7 minOct 8, 2026
AngioDynamics (ANGO) ANGO Q1 Financial Results Summary
Trending
Stocks

AngioDynamics (ANGO) ANGO Q1 Financial Results Summary

QuoteReporter
4 minOct 8, 2026
Tilray Brands (TLRY) Q1 2027 Financial Results Summary | MarketsFN